Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Recruiting · NCT05196087 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Health Network, Toronto
View the official record on ClinicalTrials.gov →What this trial is about
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with histological confirmation of a solid tumor.
- Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
- Patient must be ≥ 18 years old.
- All patients must have signed and dated an informed consent form.
Exclusion criteria
- None
Where it is running
1 location listed.
- Princess Margaret Cancer Centre - Toronto, Ontario, Canada